Clinical trials at the Eleanor N. Dana Cancer Center
Consult your medical team to find out whether you are a candidate for one of our clinical trials. Since we are constantly expanding the list of clinical trials we offer, if you don't see your cancer indication listed below please contact the Eleanor N. Dana Cancer Center at 419.383.6644. You can learn more about clinical trials here.
All Cancer Indications
Molecular Target Registry
Urothelial (Renal pelvis, Ureter, and Bladder) Cancers
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Identifier: NCT04452591
Principal Investigator: Firas Petros, MD
A Phase 2, Open-Label Study to Evaluate the Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer
Identifier: NCT05951179
Principal Investigator: Firas Petros, MD
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
Identifier: NCT06111235
Principal Investigator: Firas Petros, MD
For more information about the clinical trials that are offered at the Eleanor N. Dana Cancer Center please contact Danielle Mockensturm at 419.383.6925.